Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma

NCT01467921 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma

Interventions

DRUG: oxaliplatin

Sponsor

Samsung Medical Center